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SCIENTIFIC OPINION 
Scientific Opinion Part III on the substantiation of health claims related to 
various food(s)/food constituent(s) not supported by pertinent human data 
(ID 644, 946, 1717, 1730, 1742, 1760, 1871, 1894, 1910, 1926, 1933, 2000, 
2024, 2028, 2095, 2124, 2127, 2137, 2213, 2332, 2337, 2380, 2435, 2833, 
2917, 3072, 3075, 3080, 3129, 3193, 3636, 4037, 4044, 4313) pursuant to 
Article 13(1) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,
 
3
 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to various food(s)/food constituent(s) not supported by pertinent human data. The scientific 
substantiation is based on the information provided by the Member States in the consolidated list of 
Article 13 health claims and references that EFSA has received from Member States or directly from 
stakeholders. 
The references provided in relation to the claims evaluated in this opinion included studies which 
assessed the effects of food(s)/food constituent(s) other than the food(s)/food constituent(s) which are 
the subject of the claims, and/or investigated health outcomes unrelated to the claimed effects. No 
human studies which investigated the effects of the food(s)/food constituent(s) on appropriate 
measures of the claimed effects were provided. The Panel considers that no conclusions can be drawn 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-1431, EFSA-Q-2008-1733, EFSA-Q-2008-2453, 
EFSA-Q-2008-2466, EFSA-Q-2008-2475, EFSA-Q-2008-2493, EFSA-Q-2008-2604, EFSA-Q-2008-2627, EFSA-Q-
2008-2643, EFSA-Q-2008-2659, EFSA-Q-2008-2666, EFSA-Q-2008-2733, EFSA-Q-2008-2757, EFSA-Q-2008-2761, 
EFSA-Q-2008-2828, EFSA-Q-2008-2857, EFSA-Q-2008-2860, EFSA-Q-2008-2870, EFSA-Q-2008-2946, EFSA-Q-
2008-3065, EFSA-Q-2008-3070, EFSA-Q-2008-3113, EFSA-Q-2008-3168, EFSA-Q-2008-3566, EFSA-Q-2008-3650, 
EFSA-Q-2008-3804, EFSA-Q-2008-3807, EFSA-Q-2008-3812, EFSA-Q-2008-3861, EFSA-Q-2008-3925, EFSA-Q-
2008-4360, EFSA-Q-2008-4749, EFSA-Q-2008-4756, EFSA-Q-2010-00266, adopted on 08 April 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank the members of the Working Group on Claims for the preparatory work on 
this scientific opinion: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen.  
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from any of the references provided for the scientific substantiation of the claims evaluated in this 
opinion. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of the food(s)/food constituent(s) and the claimed effects 
evaluated in this opinion. 
KEY WORDS 
Gastro-intestinal discomfort, vision, cognitive function, upper respiratory tract, menstrual discomfort, 
menopausal discomfort, stress-induced headache, apoptosis, bacterial vaginosis, heavy metals, upper respiratory 
tract defence, health claims. 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
The approach used in the evaluation of Article 13(1) health claims is explained in the general 
guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims
6
.  
In assessing each specific food/health relationship that forms the basis of a health claim the NDA 
Panel considers the extent to which:  
1. the food/constituent is defined and characterised;  
2. the claimed effect is defined and is a beneficial physiological effect (“beneficial to human health”);  
3. a cause and effect relationship is established between the consumption of the food/constituent and 
the claimed effect (for the target group under the proposed conditions of use).  
Substantiation of the claim is dependent on a favourable outcome of the assessment of 1, 2 and 3 
above. Thus, a cause and effect relationship is considered not to be established if the outcome of any 
one of these assessments is unfavourable.  
For a claim, each relationship between a food/constituent and a claimed effect is assessed separately 
and individual assessments are combined, as appropriate, to form coherent opinions. 
1. Relevance of the claimed effect to human health 
1.1. Reduction of gastro-intestinal discomfort (ID 644, 1717, 1742, 1760, 2000, 2028, 2124, 
2213, 2337, 3072, 3075, 3080, 3193, 4313) 
The claimed effects are “digestive system”, “relief for gastric discomfort”, “zinc carnosine”, 
“relaxation”, “digestive health”, “liver health”, “digestion”, “healthy digestion”, “improvement of the 
digestion”, “santé gastro-intestinale”, and “digestive process/promotes intestinal well-being/can bind 
pathogenic bacteria/increases the activity of digestive enzymes”. The Panel assumes that the target 
population is the general population. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
6 See footnote 5 
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In the context of the proposed wordings and clarifications provided by Member States, the Panel 
assumes that the claimed effects refer to the reduction of gastro-intestinal discomfort.  
The Panel considers that reduction of gastro-intestinal discomfort is a beneficial physiological effect. 
1.2. Maintenance of normal vision (ID 2833, 4044) 
The claimed effect is “eyes”. The Panel assumes that the target population is the general population.  
In the context of the proposed wordings and clarifications provided by Member States, the Panel 
assumes that the claimed effect refers to maintenance of normal vision. 
The Panel considers that maintenance of normal vision is a beneficial physiological effect. 
1.3. Contribution to normal cognitive function (ID 1894, 1926, 2024) 
The claimed effects are “nervous system: phospholipids improve memory and cognitive functions”, 
“enhancing memory and cognitive function”, and “brain/mental/cognitive health”. The Panel assumes 
that the target population is the general population. 
In the context of the proposed wordings and clarifications provided by Member States, the Panel 
assumes that the claimed effects refer to contribution to normal cognitive function. Cognitive function 
includes memory, attention (concentration), learning, intelligence and problem solving, which are 
well defined constructs and can be measured by validated psychometric cognitive tests. 
The Panel considers that contribution to normal cognitive function is a beneficial physiological effect. 
1.4. Relief in case of irritation in the upper respiratory tract (ID 1730, 2127, 2137, 2332, 
2380, 2435) 
The claimed effects are “respiratory health” and “respiratory system health”. The Panel assumes that 
the target population is the general population. 
In the context of the proposed wordings and clarifications provided by Member States, the Panel 
assumes that the claimed effects refer to relief in case of irritation in the upper respiratory tract, which 
could be assessed if adequate validated questionnaires were available.  
The Panel considers that relief in case of irritation in the upper respiratory tract is a beneficial 
physiological effect.  
1.5. Reduction of menstrual discomfort (ID 3636) 
The claimed effect is “contributes to physical well-being”. The Panel assumes that the target 
population is women with premenstrual syndrome.  
In the context of the proposed wordings and clarifications provided by Member States, the Panel 
assumes that the claimed effect refers to a reduction in menstrual discomfort, which can be assessed 
as changes in the severity of symptoms related to the premenstrual syndrome using validated 
questionnaires. 
The Panel considers that a reduction of menstrual discomfort is a beneficial physiological effect.  
Health claims related to various food(s)/food constituent(s) 
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1.6. Reduction of menopausal discomfort (ID 1933, 2095, 3129, 3636) 
The claimed effects are “menopause”, “phytoestrogenic properties”, and “contributes to physical 
well-being”. The Panel assumes that the target population is post-menopausal women. 
In the context of the proposed wordings and clarifications provided by Member States, the Panel 
assumes that the claimed effects refer to the reduction of menopausal discomfort, which can be 
assessed as changes in the severity of symptoms related to menopause using validated questionnaires. 
The Panel considers that reduction of menopausal discomfort is a beneficial physiological effect. 
1.7. Relief from stress-induced headache (ID 4037) 
The claimed effect is “mental function and head”. The Panel assumes that the target population is the 
general population. 
In the context of the proposed wordings and clarifications provided by Member States, the Panel 
assumes that the claimed effect refers to the relief from stress-induced headache.  
The Panel considers that relief from stress-induced headache is a beneficial physiological effect. 
1.8. Apoptosis of damaged cells (ID 2917) 
The claimed effect is “induction of apoptosis of transformed and damaged cells”. The Panel assumes 
that the target population is the general population. 
In the context of the clarifications provided by Member States, the Panel assumes that the claimed 
effect refers to apoptosis of damaged cells. 
The Panel considers that apoptosis of damaged cells is a beneficial physiological effect. 
1.9. Defence against vaginal pathogens by increasing the proportion of lactobacilli and/or 
decreasing the proportion of potentially pathogenic bacteria and/or yeasts (ID 946) 
The claimed effect is “urogenital tract/natural vaginal defence”. The Panel assumes that the target 
population is the general female population. 
From the clarifications provided by Member States, the Panel assumes that the claimed effect refers to 
defence against vaginal pathogens by increasing the number of lactobacilli and/or decreasing 
potentially pathogenic bacteria and/or yeasts. 
Unlike any other anatomical site of the body, most vaginal vaults are dominated by one or more 
species of Lactobacillus. In over 70 % of women, vaginal microbiota is dominated by lactobacilli 
(> 50 %) (Ling et al., 2010; Ravel et al., 2011; Yamamoto et al., 2009). This microbiota is different 
from the more complex gut microbiota, where lactobacilli represent less than 3 % of the bacterial 
population (Franks et al., 1998; Lay et al., 2005; Sghir et al., 2000). The diagnosis of bacterial 
vaginosis (BV) is currently based on Nugent score (microscopic examination of Gram stained smear 
or vaginal discharge for bacteria and „clue‟ cells). Nugent scores are classified into normal (0-3, 
lactobacilli are present, but not Gardnerella/Bacteroides or curved Gram-negative bacilli), 
intermediate (4-6, colonisation by Bacteroides/Gardenella and curved Gram-variable rods 
(Mobiluncus)), and BV (7-10, BV with domination of Gardnerella/Bacteroides or curved Gram-
negative bacilli and absence of that lactobacilli). 
Health claims related to various food(s)/food constituent(s) 
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The Panel considers that defence against vaginal pathogens by increasing the proportion of 
lactobacilli and/or decreasing the proportion of potentially pathogenic bacteria and/or yeasts is a 
beneficial physiological effect. 
1.10. Elimination of heavy metals (ID 1871) 
The claimed effect is “alginate binds heavy metals, stimulates mucin production and protects the 
colon, N-acetylcysteine detoxifies and removes heavy metals, piperine increases the bioavailability of 
n-acetylcysteine”. The Panel assumes that the target population is the general population. 
In the context of the proposed wordings and of the references provided, the Panel assumes that the 
claimed effect refers to the elimination of heavy metals. 
The Panel considers that elimination of heavy metals is a beneficial physiological effect. 
1.11. Maintenance of the upper respiratory tract defence against pathogens by maintaining 
immune defences (ID 1910) 
The claimed effect is “immune system”. The Panel assumes that the target population is the general 
population. 
In the context of the proposed wordings and clarifications provided by Member States, the Panel 
assumes that the claimed effect refers to the maintenance of the upper respiratory tract defence against 
pathogens by maintaining immune defences. 
The Panel considers that maintenance of the upper respiratory tract defence against pathogens by 
maintaining immune defences is a beneficial physiological effect. 
2. Scientific substantiation of the claimed effect 
2.1. Reduction of gastro-intestinal discomfort (ID 644, 1717, 1742, 1760, 2000, 2028, 2124, 
2213, 2337, 3072, 3075, 3080, 3193, 4313) 
The references provided in relation to these claims were textbooks or narrative reviews which did not 
provide any original data which could be used for the scientific substantiation of the claim, or 
reported on animal or in vitro studies which addressed the effects of the food(s)/food constituent(s) 
on, e.g., spontaneous contractions of the jejunum, adhesion properties of Helicobacter pylori, 
pharmacologically or stress-induced gastric ulcers, necrotising enterocolitis, intestinal inflammation. 
One human intervention study which addressed the effects of the food(s)/food constituent(s) on the 
treatment of Helicobacter pylori infection was also provided. The Panel considers that no conclusions 
can be drawn from these references for the scientific substantiation of the claims.  
No human studies which investigated the effects of the food(s)/food constituent(s) on measures of 
gastro-intestinal discomfort were provided in relation to any of the claims evaluated in this section. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s) which are the subject of the claims evaluated in this 
section and reduction of gastro-intestinal discomfort. 
Health claims related to various food(s)/food constituent(s) 
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2.2. Maintenance of normal vision (ID 2833, 4044) 
The references provided in relation to these claims included narrative reviews, animal and in vitro 
studies on the food(s)/food constituent(s) which reported on health outcomes (e.g. systemic 
inflammation, antioxidant status, haematopoiesis, cell mutations in response to exposure to heavy 
metals) unrelated to the claimed effect. The Panel considers that no conclusions can be drawn from 
these references for the scientific substantiation of the claims. 
No human studies which investigated the effects of the food(s)/food constituent(s) on maintenance of 
normal vision were provided in relation to any of the claims evaluated in this section. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s) which are the subject of the claims evaluated in this 
section and maintenance of normal vision. 
2.3. Contribution to normal cognitive function (ID 1894, 1926, 2024) 
The references provided in relation to these claims included narrative reviews on the relationship 
between oxidative stress and age-related neuronal deficits or on the effect of different food(s)/food 
constituent(s) on memory, which did not provide any original data which could be used for the 
scientific substantiation of the claim, and on health outcomes unrelated to the claimed effect (e.g. 
anxiety). References regarding the composition of some food(s)/food constituent(s) were also 
provided. The Panel considers that no conclusions can be drawn from these references for the 
scientific substantiation of the claims. 
No human studies which investigated the effects of the food(s)/food constituent(s) on measures of 
cognitive function were provided in relation to any of the claims evaluated in this section. 
One in vitro study which assessed the effects of a food constituent on amyloid beta-peptide in 
neuronal cell cultures was provided. The Panel considers that evidence provided in in vitro studies is 
not sufficient to predict the occurrence of an effect of the consumption of the food(s)/food 
constituent(s) on contribution to normal cognitive function in vivo in humans. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s) which are the subject of the claims evaluated in this 
section and contribution to normal cognitive function. 
2.4. Relief of irritation in the upper respiratory tract (ID 1730, 2127, 2137, 2332, 2380, 
2435) 
Most of the references provided in relation to these claims were textbooks, narrative reviews and 
monographs which did not provide any original data which could be used for the scientific 
substantiation, or assessed the effects of food(s)/food constituent(s) other than those for which the 
specific claims are proposed, and/or health outcomes (e.g. treatment of infectious diseases, treatment 
of influenza) unrelated to the claimed effect. The Panel considers that no conclusions can be drawn 
from these references for the scientific substantiation of the claims. 
No human studies which investigated the effects of the food(s)/food constituent(s) on measures of 
relief of irritation in the upper respiratory tract were provided in relation to any of the claims 
evaluated in this section. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s) which are the subject of the claims evaluated in this 
section and relief of irritation in the upper respiratory tract. 
Health claims related to various food(s)/food constituent(s) 
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2.5. Reduction of menstrual discomfort (ID 3636) 
The references provided in relation to this claim were in vitro and animal studies which assessed the 
effects of food(s) other than the one which is the subject of the claim and/or health outcomes (e.g. 
antioxidant activity, apoptosis in cancer cells, antimicrobial activity) unrelated to the claimed effect. 
The Panel considers that no conclusions can be drawn from these references for the scientific 
substantiation of the claim.  
No human studies which investigated the effects of the food on reduction of menstrual discomfort 
were provided in relation to the claim evaluated in this section. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food which is the subject of the claim evaluated in this section and reduction of 
menstrual discomfort. 
2.6. Reduction of menopausal discomfort (ID 1933, 2095, 3129, 3636) 
The references provided in relation to these claims were reviews, human, animal and in vitro studies 
which assessed the effects of food(s)/food constituent(s) other than those which are the subject of the 
claim and/or health outcomes (e.g. antioxidant activity, apoptosis in cancer cells, antimicrobial 
activity) unrelated to the claimed effect. The Panel considers that no conclusions can be drawn from 
these references for the scientific substantiation of the claims. 
No human studies which investigated the effects of the food(s)/food constituent(s) on reduction of 
menopausal discomfort were provided in relation to any of the claims evaluated in this section. 
One in vitro study which investigated the oestrogenic effect of the food, which is the subject of the 
claim, was provided. The Panel considers that evidence provided in in vitro studies is not sufficient to 
predict the occurrence of an effect of the consumption of the food(s)/food constituent(s) on reduction 
of menopausal discomfort in vivo in humans. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s) which are the subject of the claims evaluated in this 
section and reduction of menopausal discomfort. 
2.7. Relief from stress-induced headache (ID 4037) 
The references provided in relation to this claim were textbooks and monographs which did not 
provide any original data which could be used for the scientific substantiation of the claim and studies 
on health outcomes (e.g. memory, regulation of body temperature, sleeping time, muscle activity) 
unrelated to the claimed effect. The Panel considers that no conclusions can be drawn from these 
references for the scientific substantiation of the claim. 
No human studies which investigated the effects of the food on relief from stress-induced headache 
were provided in relation to the claim evaluated in this section. 
Studies which assessed the effects of the food on pain in animal models were also provided. The 
Panel considers that evidence provided in animal studies is not sufficient to predict the occurrence of 
an effect of the consumption of the food on pain relief in vivo in humans. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food which is the subject of the claim evaluated in this section and relief from 
stress-induced headache.  
Health claims related to various food(s)/food constituent(s) 
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2.8. Apoptosis of damaged cells (ID 2917) 
The reference provided in relation to this claim was one in vitro study which investigated health 
outcomes (i.e. induction of the expression of breast cancer susceptibility genes and prostate cancer 
cell types) unrelated to the claimed effect. The Panel considers that no conclusions can be drawn from 
this reference for the scientific substantiation of the claim. 
No human studies which investigated the effects of the food constituent on measures of apoptosis of 
damaged cells were provided in relation to the claim evaluated in this section. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food constituent which is the subject of the claim evaluated in this section and 
apoptosis of damaged cells. 
2.9. Defence against vaginal pathogens by increasing the proportion of lactobacilli and/or 
decreasing the proportion of potentially pathogenic bacteria and/or yeasts (ID 946) 
The references provided in relation to this claim were a narrative review which did not provide any 
original data which could be used for the scientific substantiation of the claim, and a study which 
assessed the effects of food(s)/food constituent(s) other than the food constituent for which the 
specific claim is proposed. The Panel considers that no conclusions can be drawn from these 
references for the scientific substantiation of the claim. 
No human studies which investigated the effect of the food constituent on the proportion of 
lactobacilli and/or potentially pathogenic bacteria and/or yeasts in the vagina were provided in 
relation to the claim evaluated in this section. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food constituent which is the subject of the claim evaluated in this section and 
defence against vaginal pathogens by increasing the proportion of lactobacilli and/or decreasing the 
proportion of potentially pathogenic bacteria and/or yeasts. 
2.10. Elimination of heavy metals (ID 1871) 
The references provided in relation to this claim were studies which assessed the effects of 
food(s)/food constituent(s) other than the specific combination of food constituents which is the 
subject of the claim. The Panel considers that no conclusions can be drawn from these references for 
the scientific substantiation of the claim. 
No human studies which investigated the effects of the specific combination of food constituents on 
elimination of heavy metals were provided in relation to the claim evaluated in this section. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the specific combination of food constituents which is the subject of the claim 
evaluated in this section and elimination of heavy metals. 
2.11. Maintenance of the upper respiratory tract defence against pathogens by maintaining 
immune defences (ID 1910) 
The references provided in relation to this claim included narrative reviews and animal studies which 
addressed health outcomes (e.g. tumour regression) unrelated to the claimed effect, and a non-
scientific reference (web page of a food producer) which did not provide any original data for the 
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scientific substantiation of the claim. The Panel considers that no conclusions can be drawn from 
these references for the scientific substantiation of the claim. 
No human studies which investigated the effects of the food constituent on maintenance of the upper 
respiratory tract defence against pathogens by maintaining immune defences were provided in relation 
to the claim evaluated in this section. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food constituent which is the subject of the claim evaluated in this section and 
maintenance of the upper respiratory tract defence against pathogens by maintaining immune 
defences.  
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 A cause and effect relationship has not been established between the consumption of the 
food(s)/food constituent(s) and the claimed effects evaluated in this opinion. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-1431, 
EFSA-Q-2008-1733, EFSA-Q-2008-2453, EFSA-Q-2008-2466, EFSA-Q-2008-2475, EFSA-Q-2008-
2493, EFSA-Q-2008-2604, EFSA-Q-2008-2627, EFSA-Q-2008-2643, EFSA-Q-2008-2659, EFSA-Q-
2008-2666, EFSA-Q-2008-2733, EFSA-Q-2008-2757, EFSA-Q-2008-2761, EFSA-Q-2008-2828, 
EFSA-Q-2008-2857, EFSA-Q-2008-2860, EFSA-Q-2008-2870, EFSA-Q-2008-2946, EFSA-Q-2008-
3065, EFSA-Q-2008-3070, EFSA-Q-2008-3113, EFSA-Q-2008-3168, EFSA-Q-2008-3566, EFSA-Q-
2008-3650, EFSA-Q-2008-3804, EFSA-Q-2008-3807, EFSA-Q-2008-3812, EFSA-Q-2008-3861, 
EFSA-Q-2008-3925, EFSA-Q-2008-4360, EFSA-Q-2008-4749, EFSA-Q-2008-4756, EFSA-Q-2010-
00266). The scientific substantiation is based on the information provided by the Member States in 
the consolidated list of Article 13 health claims and references that EFSA has received from Member 
States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
7
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health". 
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be: 
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3). 
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
8
  
Foods are commonly involved in many different functions
9
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent. 
                                                     
7 OJ L12, 18/01/2007 
8 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
9 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).  
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect. 
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects: 
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent. 
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
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consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to various food(s)/food constituent(s) that are not supported 
by pertinent human data, including conditions of use from similar claims, as proposed in the 
Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
644 Milk fat globule 
membrane/Milk 
phospholipids. 
Digestive system. Supports intestinal comfort. 
Supports the functioning of the 
digestive system. 
Conditions of use 
- 100mg phospholipids per serving. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
946 Lactobacillus acidophilus 
LA14  
Urogenital tract /Natural 
vaginal defence  
Clarification provided 
Urogenital tract /Natural 
vaginal defence 
Contributes to a healthy 
colonization of 
lactobacilli in the vagina 
Helps to redress the 
healthy balanced vaginal 
microflora during and 
after the treatment of 
urogenital disorders 
Helps to restore and maintain normal 
vaginal microflora;  
Helps during the treatment of 
urogenital disorders;  
Conditions of use 
- mind.1x10E9 KBE/Tag 
- at least 1x109 cfu/day  
Comments from Member States 
GE proposal identical to first Dutch proposal 
ID Food or Food constituent Health Relationship Proposed wording 
1717 Chlorophyllin 
[Sodium copper 
chlorophyllin]. 
Relief for Gastric 
Discomfort. 
“Provides antioxidant protection.” 
“For daily detoxification support.”  
“Research indicates that 
chlorophyllin may modulate the 
activity of detoxification enzymes 
and provide antioxidant protection 
against free radicals.” 
Conditions of use 
- The recommended daily dosage: 50 – 150 mg/day. 
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ID Food or Food constituent Health Relationship Proposed wording 
1730 Glycerol. Respiratory health. Soothing for mouth and throat. 
Reliefs in case of tickle in the throat 
and pharynx. 
Soothing and pleasant effect on 
throat, pharynx and vocal cords. 
Conditions of use 
- none provided 
ID Food or Food constituent Health Relationship Proposed wording 
1742 Milk fat globule 
membrane/Milk 
phospholipids. 
Digestive system. Supports intestinal comfort. 
Supports the functioning of the 
digestive system. 
Conditions of use 
- 100mg phospholipids per serving. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
1760 Zinc carnosine. Zinc carnosine. Gastric comfort. 
Supports a healthy gastric 
environment. 
Zinc-carnosine supports the natural 
defenses and healthy ecology of the 
gastric lining. 
Conditions of use 
- The recommended daily dosage: 150 mg zinc-carnosine (including 32 mg zinc). 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
1871 Name of Food product: 
Product-specific claim: 
sodium alginate, n-acetyl 
cysteine and piperine 
Description of food in 
terms of food legislation 
categories: food not 
covered by specific food 
legislation 
Was food on Irish market 
before 1st July 2007: No 
Health benefits of food: 
Alginate binds heavy 
metals, stimulates mucin 
production and protects 
the colon. N-
acetylcysteine detoxifies 
and removes heavy 
metals. Piperine increases 
the bioavailability of n-
acetylcysteine. 
Do benefits relate to a 
disease risk factor: No 
Target group: Adults 
aged 18 years and over 
with some exceptions 
If exceptions describe: 
Pregnant, lactating 
Exact wording of claim as it appears 
on product: Supports body 
detoxification 
Examples of any alternative wording 
that may be used in relation to claim: 
Rids toxins from the body/Aids 
colonic health/Protects the 
colon/Cleanses the body/Helps 
maintain a healthy colon/Promotes 
healthy conditions in the 
colon/Detoxes the body 
Is claim a picture: No 
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women and children 
Reasons for excluding 
these groups: Alginate 
may decrease the 
absorption of calcium if 
taken concomitantly 
therefore it should be 
avoided by pregnant, 
lactating women and 
children and those with 
calcium deficiency or 
brittle bones. When 
taking N-acetyl cysteine 
it is recommended that 
two to three times as 
much vitamin C be taken 
at the same time. Failure 
to do so may result in 
more harm than good 
from taking this product 
because of the prolonged 
presence of the oxidized 
form of L-Cysteine. 
Conditions of use 
- Number of nutrients/other substances that are essential to claimed effect: 3. Names of 
nutrient/other substances and Quantity in Average daily serving: 5g sodium alginate, 600 
mg n-acetyl cysteine,  15 mg piperine. Weight of average daily food serving:   150 
mililitre(s). Daily amount to be consumed to produce claimed effect:   450 mililitre(s). 
Number of food portions this equates to in everyday food portions:     1. Are there factors 
that could interfere with bioavailability: Yes. Please give reason: Alginate forms a gel in the 
stomach and it may trap a portion of N-acetyl-cysteine. Piperine increases the 
bioavailability of the untrapped portion of N-acetyl cysteine thus increaing its efficacy. 
Length of time after consumption for claimed effect to become apparent: up to 6 weeks. Is 
there a limit to the amount of food which should be consumed in order to avoid adverse 
health effects: Don't Know. Where applicable outline nutritional composition (g per 100g) 
of food: Total Fat:      .01, Saturated Fat:      .00, Trans Fat:      .00, Sugar:      .31, Salt:      
.00, Sodium:      .01. Other conditions for use: This beverage must be consumed as part of a 
varied, balanced and healthy lifestyle. Three beverages are to be consumed daily in order to 
gain benefit. This product should be avoided by pregnant, lactating women and children 
and those with calcium deficiency or brittle bones. 
No clarification provided by Member States 
Comments provided by Member States 
Further clarification to support the use of this claim was not submitted to the Food Safety 
Authority of Ireland. The FBO involved did submit further information on other claims and 
remarked in relation to the comment from EFSA that this claim is 'too vague', that they felt that 
the information they already provided is quite specific. 
ID Food or Food constituent Health Relationship Proposed wording 
1894 Laitance de poisson. 
Clarification provided 
Lipids of fish gonads 
Système nerveux, 
Mémoire, source de 
protéines-lipides dont des 
Contribue à stimuler l‟activité 
intellectuelle et à renforcer la 
mémoire. 
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(phospholipids: 
phosphatidylserine, 
phosphatidylethanolamine 
and phosphatidylcholine). 
phospholipides. 
Clarification provided 
Nervous system: 
phospholipids improve 
memory and cognitive 
functions. 
A utiliser en cas d'efforts 
intellectuels. 
Favorise les facultés de 
concentration. 
Clarification provided 
May improve memory/may improve 
cognitive performance/ phospholipids 
play a role in healthy brain 
functions/supports memory and 
concentration/increase concentration 
and make the memory more effective. 
Conditions of use 
- 6x250mg/jour. 
ID Food or Food constituent Health Relationship Proposed wording 
1910 WGP beta-glucan;(WGP® 
(1,3)-b-D-glucan);(from 
Saccharomy-ces 
cerevisiae). 
Immune system. 
Clarification provided 
Immune system; WGP 
beta -glucan stimulates 
the white blood cells 
(macrophages and 
ganulocytes) thus 
improve the function of 
the immune system. 
WGP beta-glucan contributes to the 
normal function of the immune 
system. WGP beta-glucan naturally 
contributes to adequate immune 
responses. The daily dietary 
supplementation with WGP beta-
glucan promotes the normal function 
of the immune system. WPG beta-
glucan enhances the production and 
activity of the macrophages and 
neutrophiles. Thus, it plays an 
important role in the adequate 
function of the immune system. WGP 
beta-glucan contributes to maitain the 
normal function of upper respiratoy 
tract. 
Conditions of use 
- 250-500 mg per day for adults; 125 mg per day for children. 
ID Food or Food constituent Health Relationship Proposed wording 
1926 Homotaurine. Enhancing memory and 
cognitive function. 
Homotaurine has been shown to help 
maintain cognitive function. 
Conditions of use 
- 50 to 300 mg/diem in a food supplement formulation. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
1933 Mung bean (Vigna 
Radiata) 
Menopause 
Clarification provided 
Necessary to help women 
cope with the signs 
associated with the 
menopause, such as 
Phytoestrogens are commonly used 
by women who cannot / do not want 
to use HRT during menopause. PB is 
a source of phytoestrogens. PB is a 
source of oestrogenic support during 
menopause and beyond. Oestrogenic 
support during menopause years and 
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disturbed sleep, lethargy 
and irritability 
Necessary for a calm and 
comfortable menopause.  
Helps women coping 
with the teltale 
signsassociated with 
menopause, such as hot 
flushes, sweating, 
restlessness and 
irritablity. 
beyond which helps maintain 
wellbeing and quality of life. 
Conditions of use 
- Suitable for healthy women during menopause years and beyond. First 4-6 weeks: 2 
capsules twice daily, thereafter as required to maintain wellbeing. Women on medication 
should seek the advice of their GP prior to including Product in their diet (full information 
pack available for GPs from suppliers). (For additional details, please refer to Background 
Information). 
ID Food or Food constituent Health Relationship Proposed wording 
2000 Aspalathus linearis 
(Common Name : 
Rooibos/Red bush). 
Relaxation. 
Clarification provided 
Spasmolytic - helps 
maintain intestinal 
comfort by reducing 
abdominal spasm and 
diarrhoea. 
Contributes to optimal relaxation 
/ helps to support the relaxation. 
Conditions of use 
- liście/ zwykle konsumowane jako tradycyjny artykuł żywnościowy w normalnej diecie. 
- Monoprodukt oder Zutat einer Mischung, zur Zubereitung eines Heißaufgusses. 
- Leaf / Usual consumption as traditional foodstuff in a normal diet. 
ID Food or Food constituent Health Relationship Proposed wording 
2024 Cherries (Prunus cerasus, 
P. domestica), including 
Montmorency, Balaton or 
other sour/tart cherry 
varieties. 
Brain/mental/cognitive 
health. 
Clarification provided 
Anxiolytic and 
antioxidant effects: 
Decrease in anxiety-
related behaviors. 
Increases visuo-spatial 
task performance (in 
rats). 
[Tart/sour] cherries help support 
healthy brain / mental function. 
Conditions of use 
- Variable, depending on formulation e.g. concentrate for dilution in water (typically 30 ml 
per day) or freeze-dried extract (typically, 1-2 capsules daily) 
ID Food or Food constituent Health Relationship Proposed wording 
2028 Citrus limon (Common Digestive health. Helps to support the digestion 
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Name: Lemon). Clarification provided 
Reduces gastrointestinal 
spasms and stimulates 
salivary, biliary and 
pancreatic secretions  . 
contributes to the normal function of 
intestinal tract  
helps support the digestive juice 
flow. 
Conditions of use 
- Skórka/ Zwykle konsumowana jako tradycyjny artykuł żywnościowy w normalnej diecie. 
- Peel / Usual consumption as tradtional foodstuf in a normal diet. 
- Schale /  Üblicher Verzehr als traditionelles Lebensmittel im Rahmen einer ausgewogenen 
Ernährung. 
Comments from Member States 
DE received new literature from applicant (available via FIS-VL: 
https://fisvl.bund.de/Members/irc/fisvl/healthclaims/library?l=/datenbank/anlagen_datenbank_hi
ngewiesen_wi/nachgereichte_literatur/haupteintrag_2028/1246959776dosier/_DE_1.0_&a=d). 
ID Food or Food constituent Health Relationship Proposed wording 
2095 Mung bean (Vigna 
Radiata) 
Menopause 
Clarification provided 
Necessary to help women 
cope with the signs 
associated with the 
menopause, such as 
disturbed sleep, lethargy 
and irritability 
Necessary for a calm and 
comfortable menopause.  
Helps women coping 
with the teltale 
signsassociated with 
menopause, such as hot 
flushes, 
sweating, restlessness and 
irritablity. 
Phytoestrogens are commonly used 
by women who cannot / do not want 
to use HRT during menopause. PB is 
a source of phytoestrogens. PB is a 
source of oestrogenic support during 
menopause and beyond. Oestrogenic 
support during menopause years and 
beyond which helps maintain 
wellbeing and quality of life. 
Conditions of use 
- Suitable for healthy women during menopause years and beyond. First 4-6 weeks: 2 
capsules twice daily, thereafter as required to maintain wellbeing. Women on medication 
should seek the advice of their GP prior to including Product in their diet (full information 
pack available for GPs from suppliers). (For additional details, please refer to Background 
Information). Product should not be included in women's diet if they are pregnant, or 
planning a pregnancy, taking contraceptives or HRT. Product should not be consumed by 
women with low blood pressure, oestrogen or over-active thyroid related disorders or using 
blood thinners/anticoagulants. Product may cause initial discomfort, wind and bloating in 
women with low dietary intake or intolerance of legumes/pulses. 
ID Food or Food constituent Health Relationship Proposed wording 
2124 Raphanus sativus var niger 
(Common Name : Radish, 
Black radish, Japanese 
Liver health. 
Clarification provided 
Contributes to the elimination 
function of the gastrointestinal tract / 
contributes to bile flow fonction / 
Health claims related to various food(s)/food constituent(s) 
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radish, Daikon). Liver health/ Liver 
health/ Contribute to have 
a good function of the 
upper digestive tract,to a 
good gall bladder 
function. 
Promotes / contribute to a 
normal biliary flow for 
the digestive well-
being/comfort. 
Help to drain the liver 
and gall bladder. 
supports healthy liver activity / 
contributes to healthy 
digestion/digestive well-beingl/liver 
well-being. 
Conditions of use 
- Wurzel / Äquivalent von  45-100 ml ausgepresstem Saft. 
- korzeń/ równowartość 45- 100 ml wyciśniętego soku z korzenia. 
- Root / The equivalenty of 45-100 ml pressed root juice. 
- Racine 50-100ml jus/jour. 
Comments from Member States 
Several entries with the same or similar wording have NO comments of EFSA (0)  (see for 
examples entries n°: 2186, 
2227,2258,2260,2658,2694,2858,3391,3436,3721,3733,3947,3952,,,) Therefore, these entries 
2124, 2329 and 2752 do not have to have the EFSA comment n°3. 
ID Food or Food constituent Health Relationship Proposed wording 
2127 Rubus fructicosus L. 
(Common name: 
Blackberry). 
Respiratory health. Soothing for mouth and throat / 
Reliefs in case of irritation of throat 
and pharynx / Soothing and pleasant 
effect on throat, pharynx and vocal 
cords. 
Conditions of use 
- Folia (Leaves) 4 to 5 g dried drug equivalent per day 
- Folia–(Blätter)––usual consumption as a traditional foodstuff in a normal diet (cough 
drops)––4 bis 5 g der getrockneten Pflanzenteile (Droge) pro Tag. 
ID Food or Food constituent Health Relationship Proposed wording 
2137 Sambucus nigra (Common 
Name : Elderberry) 
Respiratory health 
Clarification provided 
Respiratory health. 
Used to promote 
respiratory comfort. 
Soothing for mouth and 
throat/ Relieves in case of 
tickle in the throat and 
pharynx / Soothing and 
pleasant effect on throat, 
pharynx and vocal cords. 
helps to soothe common 
cold/pleasant for cough and 
croakiness 
Health claims related to various food(s)/food constituent(s) 
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Conditions of use 
- owoc, kwiaty/ zwykle konsumowane jako tradycyjny artykuł żywnościowy w normalnej 
diecie/ równowartość 5g kwiatów lub owoców na dzień 
- Fructus–(Frucht)––usual consumption as a traditional foodstuff in a normal diet (cough 
drops). 
- Flos–(Blüten)––usual consumption as a traditional foodstuff in a normal diet (cough drops). 
10 bis 15 g der getrockneten Pflanzenteile (Droge) pro Tag. 
- 39 mg/kg KG, usual consumption as traditional foodstuff in a normal diet. 
- Fruit, flowers / Usual consumption as traditional foodstuff in a normal diet / The equivalent 
of 5 gram flowers or berries per day. 
- Fleur 10-15g/jour en infusion 
- Fructus (Fruit) 
- Flos (Flowers) 10 to 15 g dried drug equivalent per day 
ID Food or Food constituent Health Relationship Proposed wording 
2213 Ananas comosus - common 
name: Bromelain, 
Pineapple. 
Digestion. 
Clarification provided 
Reduces gastrointestinal 
discomfort. 
"Used to facilitate the digestion" / 
"Contributes to the digestive 
comfort" / "Helps to support the 
digestion" / "Contributes to support 
the digestion". 
Conditions of use 
- Traditional use of the fruit / 80-320mg of bromelain two to three times daily for 8 to 10 
days / Equivalent quantity in extract. 
- Extract of fruit: 200 - 400 mg / Used as part of a multibotanical combination. 
- Tige 6x280mg/jour. 
- Fruit / 160-960 mg of bromelain daily for 8 to 10 days / Equivalent quantity in extract. 
Comments from Member States 
Claims 2122, 4106, 2109, 2014, 3948 have the same relationship and comment 0. 
ID Food or Food constituent Health Relationship Proposed wording 
2332 Ribes nigrum L. 
(Common name: 
Blackcurrant). 
Respiratory health. Soothing for mouth and throat / 
Reliefs in case of tickle in the throat 
and pharynx / Soothing and pleasant 
effect on throat, pharynx and vocal 
cords. 
Conditions of use 
- Fructus (Fruit) 
ID Food or Food constituent Health Relationship Proposed wording 
2337 Rubus idaeus - common 
name: Blackberry 
Digestion Used to facilitate the digestion"  
"Contributes to the digestive 
comfort"  
"Helps to support the digestion"  
"Contributes to support the 
Health claims related to various food(s)/food constituent(s) 
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digestion". 
Conditions of use 
- Traditional use of the leaf / 1,5g of leaves as an infusion / Equivalent quantity in extract 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
2380 Horseradish root 
(Armoracia rusticana)  
Respiratory system health 
Clarification provided 
Respiratory system health 
Active ingredients of 
horseradish support 
healthy functioning of 
upper respiratory system, 
free air-flow, and are 
prosperous to soothe 
irritation of their mucous 
membranes. Horseradish 
root has antimicrobial 
properties.  
Active ingredients of horseradish can 
support the respiratory system health. 
Conditions of use 
- 20 g/ day fresh horseradish root or 120mg / day horseradish root extract 
- Racine. 6x125mg/jour  
Comments from Member States 
Exemple of wording: Helps to maintain the integrity of the respiratory tract thanks its 
antimicrobial effects 
ID Food or Food constituent Health Relationship Proposed wording 
2435 Emblica officinalis (Indian 
Gooseberry) 
Respiratory health Softens the mucous membrane of 
throat 
Conditions of use 
- Fruit extract (dry): 10- 100 mg / Used as part of a multibotanical combination 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
2833 Wheat sprouts Eyes For eye health. 
Conditions of use 
- Food supplement with 600-1200mg of wheat sprout powder in the daily dose. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
2917 Indole-3-carbinol Induction of apoptosis of 
transformed and 
damanged cells 
Clarification provided 
Support of selective 
Indole-3-carbinol supports the regular 
fenotype of cells and positively 
affects the induction of apoptosis of 
damaged cells 
Health claims related to various food(s)/food constituent(s) 
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apoptose( programmed  
cell  death ) of 
oncogenous cells 
Conditions of use 
- 150 - 450mg daily 
ID Food or Food constituent Health Relationship Proposed wording 
3072 Beta vulgaris (red beet 
juice, lactic acid 
fermented) 
Healthy digestion 
Clarification provided 
Beta vulgaris helps 
maintain normal bowel 
gas and comfort  
Supports a healthy digestion. 
Conditions of use 
- At least 1 glass ( = 150 ml) lactic acid fermented pure beet juice per day 
Comments from Member States 
Additionally the example of wording is modified as follows: Helps maintain normal bowel gas 
and comfort  
ID Food or Food constituent Health Relationship Proposed wording 
3075 Beta carota (carrot juice, 
lactic acid fermented) 
Healthy digestion 
Clarification provided 
Beta vulgaris helps 
maintain normal bowel 
gas and comfort  
Supports a healthy digestion. 
Conditions of use 
- At least 1 glass ( = 150 ml) lactic acid fermented carrot juice per day 
Comments from Member States 
Additionally the example of wording is modified as follows: Helps maintain normal bowel gas 
and comfort  
ID Food or Food constituent Health Relationship Proposed wording 
3080 –Papayafruchtfleisch 
(CARICOL®)–
ballaststoffreiche 
Fruchtzubereitung, 
hergestellt aus dem 
Fruchtfleisch baumgereifter 
Papayafrüchte nach einem 
international patentierten 
Verfahren 
(PCT/IB2003/005476).––
CARICOL® ist eine 
international geschützte 
Marke (820.278) ––CG 
06––– 
Clarification provided 
–Verbesserung der 
Verdauung CT 15 
Clarification provided 
Improvement of the 
digestion.  
Zur natürlichen Unterstützung und 
Regulierung der Verdauung, 
insbesondere bei  der Neigung zu 
Blähungen, Sodbrennen, hartem oder 
ungeformtem Stuhl. 
Verbessert die Verdauung. 
Clarification provided 
Naturally supports and regulates the 
digestive system, especially relating 
to excessive flatulence or gas, or a 
tendency towards loose stool, 
constipation or heart burn.  
Improves the digestion. 
Health claims related to various food(s)/food constituent(s) 
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CARICOL® 
a fruit preparation, rich in 
dietary fiber prepared from 
the mature flesh tree 
ripened papayas according 
to an international patented 
procedure. 
(PCT/IB2003/005476). 
CARICOL® is an 
international registered 
trademark (820.278)  
Conditions of use 
- Herstellung gemäß patentiertem Verfahren.––Tagesdosis–20-60ml–nach den Mahlzeiten.– 
ID Food or Food constituent Health Relationship Proposed wording 
3129 Lignans  Phyto-estrogenic 
properties  
Clarification provided 
Phyto-estrogenic 
properties: Contain 
phytonutrients that act as 
phytoestrogens. 
Maintains a calm and 
comfortable menopause 
(e.g. helps coping with 
hotflushes, night sweats) 
Phytonutrients that show similar 
attributes to phytoestrogens in soya. 
Conditions of use 
- 2 mg/serving  
ID Food or Food constituent Health Relationship Proposed wording 
3193  Graines de brocoli et 
extraits de graines de 
brocoli 
 Santé gastro-intestinale Le sulforaphane aide à maintenir la 
santé gastro-intestinale. Il apporte  un 
effet bénéfique sur la santé gastro-
intestinale. 
Conditions of use 
- Graines  et extraits de graines  de brocoli / équivalent  de 100 à 500 mg de sulforaphane  
par jour 
ID Food or Food constituent Health Relationship Proposed wording 
3636 VACCINIUM VITIS-
IDAEA L.  
Contributes to physical 
well-being 
Clarification provided 
Relaxation 
Helps during the premenstrual 
cycle.Contributes to relieve the 
menopause symptoms 
Conditions of use 
- 2-5 g fruits daily; decoction: 1 g leaves in 100 ml water, 2-3 tablespoons 2-3 times daily; 5-
20 drops fresh leaves macerated in glycerine and alcohol, for min. 3 months 
ID Food or Food constituent Health Relationship Proposed wording 
Health claims related to various food(s)/food constituent(s) 
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4037 Emblica officinalis FRUIT 
RIND 
Mental function & Head 
Clarification provided 
Its anodyne effect helps 
keep the head free from 
pain.  
Supports mental function. Helps 
maintain freedom from pain in the 
head. Improves the body's resistance 
to stress. Helps the body to deal with 
stress 
Conditions of use 
- Powder 3-0.2 g/day; aqueous extra 1.5-0.1 g/day. All over 2 years old:  2-4 years ¼ adult 
dose, 4-10 years half adult dose 
ID Food or Food constituent Health Relationship Proposed wording 
4044 Emblica officinalis FRUIT 
RIND 
Eyes 
Clarification provided 
Helps protect the eyes 
from oxidative stress.  
Supports eye function 
Conditions of use 
- Powder 3-0.2 g/day; aqueous extra 1.5-0.1 g/day. All over 2 years old:  2-4 years ¼ adult 
dose, 4-10 years half adult dose 
ID Food or Food constituent Health Relationship Proposed wording 
4313 Brewer's yeast 
(Saccharomyces cerevisae) 
Digestive 
process/promotes 
intestinal well-being/can 
bind pathogenic 
bacteria/increases the 
activity of digestive 
enzymes 
Contribute to a normal intestinal 
fonction through promotion of 
beneficial microflora/helps to manage 
diarrhea episodes/has an anti-
diarrheal effect through anti-
microbial activity on pathogenic 
intestinal bacteria. 
Conditions of use 
- 250-500 mg/day 
 
Health claims related to various food(s)/food constituent(s) 
not supported by pertinent human data (Part III)   
 
31 EFSA Journal 2011;9(6):2248 
GLOSSARY AND ABBREVIATIONS 
BV Bacterial vaginosis 
 
 
